Qiagen Launches Portfolio of Environmentally Friendly Nucleic Acid Extraction Kits
By LabMedica International staff writers Posted on 21 Jan 2022 |
QIAGEN N.V. (Venlo, Netherlands) has launched its new QIAwave product line of three nucleic acid extraction kits that use fewer components and produce less waste than existing ones. They are the first of their type to use both recycled plastics and space-saving chemical concentrates.
The QIAwave RNA Mini Kit, QIAwave DNA Blood & Tissue Kit and QIAwave Plasmid Miniprep Kit use up to 63% less plastic and up to 42% less cardboard than QIAGEN’s most popular kits for extracting DNA, RNA and plasmid DNA from samples. That makes them a more sustainable alternative to existing products – a major step in reducing the environmental impact of QIAGEN’s overall portfolio.
The new QIAwave products feature fewer components, waste tubes made from 100% recycled plastic, and suitable buffer concentrates in smaller bottles, rather than ready-to-go mixes. More compact kits and new ways of packing them reduce the amount of cardboard needed to box them up.
“QIAwave products are designed in collaboration with our customers to tackle the persistent problem of laboratory waste faced by scientists all over the world,” said Thomas Schweins, Senior Vice President, Head of Life Sciences. “These three kits are the first in a wave of continuous improvements and product evolutions that will reduce the environmental footprint of our products, while still delivering the same QIAGEN quality.”
Related Links:
QIAGEN N.V.
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans